Analysts Issue Forecasts for FHTX Q1 Earnings

Key Points

• Wedbush analysts forecast Foghorn Therapeutics Inc. will report Q1 2026 earnings of ($0.25) per share, with a full-year estimate of ($1.55) per share.
• Foghorn Therapeutics recently beat earnings expectations, reporting ($0.28) EPS for its last quarter, surpassing the consensus estimate of ($0.31) by $0.03.
• The company has a current consensus rating of "Buy" and a price target of $12.13, with eight analysts recommending buy or outperform ratings.

Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Equities researchers at Wedbush issued their Q1 2026 earnings estimates for Foghorn Therapeutics in a note issued to investors on Tuesday, August 5th. Wedbush analyst R. Driscoll anticipates that the company will post earnings per share of ($0.25) for the quarter. The consensus estimate for Foghorn Therapeutics' current full-year earnings is ($1.55) per share. Wedbush also issued estimates for Foghorn Therapeutics' Q2 2026 earnings at ($0.26) EPS, Q3 2026 earnings at ($0.23) EPS and Q4 2026 earnings at ($0.23) EPS.

Foghorn Therapeutics (NASDAQ:FHTX - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported ($0.28) EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.03. The firm had revenue of $7.56 million for the quarter, compared to analyst estimates of $7.62 million.

Other equities analysts have also recently issued reports about the stock. Citizens Jmp assumed coverage on shares of Foghorn Therapeutics in a report on Wednesday, April 23rd. They issued a "mkt outperform" rating and a $9.00 target price on the stock. HC Wainwright upgraded shares of Foghorn Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. JMP Securities reaffirmed a "market outperform" rating and issued a $9.00 target price on shares of Foghorn Therapeutics in a report on Thursday, May 15th. Finally, Citigroup began coverage on Foghorn Therapeutics in a report on Wednesday, April 23rd. They set an "outperform" rating on the stock. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Foghorn Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $12.13.

Foghorn Therapeutics Stock Performance

NASDAQ FHTX traded down $0.11 on Wednesday, reaching $4.88. The stock had a trading volume of 6,986 shares, compared to its average volume of 131,218. The stock has a market cap of $275.58 million, a P/E ratio of -4.10 and a beta of 3.05. Foghorn Therapeutics has a 12-month low of $2.94 and a 12-month high of $10.25. The business's 50-day moving average price is $5.12 and its 200 day moving average price is $4.58.

Institutional Investors Weigh In On Foghorn Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of FHTX. Bank of America Corp DE increased its holdings in shares of Foghorn Therapeutics by 14.5% in the 4th quarter. Bank of America Corp DE now owns 31,662 shares of the company's stock valued at $149,000 after purchasing an additional 4,002 shares in the last quarter. D. E. Shaw & Co. Inc. lifted its position in shares of Foghorn Therapeutics by 44.0% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 100,367 shares of the company's stock valued at $474,000 after acquiring an additional 30,671 shares during the period. BNP Paribas Financial Markets acquired a new stake in shares of Foghorn Therapeutics during the 4th quarter valued at approximately $61,000. Lazard Asset Management LLC purchased a new stake in shares of Foghorn Therapeutics during the 4th quarter worth approximately $49,000. Finally, Geode Capital Management LLC grew its holdings in shares of Foghorn Therapeutics by 0.8% in the 4th quarter. Geode Capital Management LLC now owns 682,863 shares of the company's stock worth $3,224,000 after acquiring an additional 5,477 shares during the period. Institutional investors and hedge funds own 61.55% of the company's stock.

About Foghorn Therapeutics

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.